Lung Cancer Trial, Recruiting (NCT06726720)

Lung Cancer Trial, Recruiting NCT06726720 Sponsor: AstraZeneca Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06726720 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 or older
People who have been diagnosed with non-small cell lung cancer (a type of lung cancer) confirmed through a laboratory test of tissue or cell samples
People who have recently started (within the past three weeks or at the time of enrolment) a treatment approved by or developed in partnership with AstraZeneca
People who have been fully informed about the study and have signed a consent form agreeing to take part, in line with local rules

Who may not be able to join:

People who are currently taking part in another clinical trial that involves an active treatment for non-small cell lung cancer (though participation in certain lower-involvement studies that do not affect the lung cancer treatment may be an exception — confirm with trial site)
People who are already enrolled in another section (module) of the UMBREALUNG study
People who are under a legal protection measure, such as court-ordered supervision, curatorship, or guardianship

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 9 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06726720

Sponsor: AstraZeneca

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

Trial contact: 1-877-240-9479

More information: https://clinicaltrials.gov/study/NCT06726720

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 or older
People who have been diagnosed with non-small cell lung cancer (a type of lung cancer) confirmed through a laboratory test of tissue or cell samples
People who have recently started (within the past three weeks or at the time of enrolment) a treatment approved by or developed in partnership with AstraZeneca
People who have been fully informed about the study and have signed a consent form agreeing to take part, in line with local rules

Who may not be able to join:

People who are currently taking part in another clinical trial that involves an active treatment for non-small cell lung cancer (though participation in certain lower-involvement studies that do not affect the lung cancer treatment may be an exception — confirm with trial site)
People who are already enrolled in another section (module) of the UMBREALUNG study
People who are under a legal protection measure, such as court-ordered supervision, curatorship, or guardianship

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 9 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

AstraZeneca

Registry

ClinicalTrials.gov

Start date

16 December 2024

Est. completion

30 June 2032

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Cohort A (resectable NSCLC)-Adjuvant rw DFS; Cohort A (resectable NSCLC)- Peri-operative rw EFS; Cohort B (unresectable NSCLC): median rwTFST; Cohort C (metastatic NSCLC) rw TFST

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov